Signals, Powered By EquityPandit
Zydus Cadila, has received final approval from US health regulator to market Dexmedetomidine Hydrochloride injection.
The company in a regulatory filing stated that, the approval is to market Dexmedetomidine Hydrochloride injection 200 mcg (base)/2 ML and 100 mcg (base)/ ML single dose virals. It is used for sedation of intubated and mechanically ventilated patients.
Furthermore, the injection will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahemdabad.
